COVID-19, adaptative immune response and metabolic-associated liver disease

Luca Miele*, Cecilia Napodano, Alfredo Cesario, Antonio De Magistris, Krizia Pocino, Umberto Basile, Gian Ludovico Rapaccini, Antonio Gasbarrini, Antonio Grieco

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.
Lingua originaleEnglish
pagine (da-a)2560-2577
Numero di pagine18
RivistaLiver International
Stato di pubblicazionePubblicato - 2021


  • COVID-19
  • immune response
  • liver function tests


Entra nei temi di ricerca di 'COVID-19, adaptative immune response and metabolic-associated liver disease'. Insieme formano una fingerprint unica.

Cita questo